Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
National Cancer Institute (NCI)
OBJECTIVES:
* Establish the efficacy of high-dose three-dimensional conformal radiotherapy in patients with intermediate prognostic risk adenocarcinoma of the prostate.
* Determine the PSA relapse-free survival rate of this patient population.
OUTLINE: Patients receive high-dose three-dimensional conformal radiotherapy 4-5 days per week for at least 9 weeks.
Patients are evaluated at least weekly during radiotherapy and at 2 and 4 months after treatment completion. Thereafter, patients are followed every 6 months for a total of 3 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically proven intermediate prognostic risk (T1-T2) adenocarcinoma of the prostate
* Previously untreated (except for hormonal therapy)
* PSA levels greater than 10 ng/mL and Gleason scores no greater than 6 OR
* PSA levels no greater than 10 ng/mL and Gleason scores at least 7
* Patients requiring volume reduction of prostate prior to radiotherapy continue to be treated at least 3 months on neoadjuvant hormonal therapy prior to radiation
No evidence of distant metastases
No regional lymph node involvement
PATIENT CHARACTERISTICS:
Age:
Not specified
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Not specified
Hepatic:
Not specified
Renal:
Not specified
Other:
No major medical illness
No psychosis
No metallic pelvic prosthesis
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
No prior chemotherapy
Endocrine therapy:
See Disease Characteristics
Prior neoadjuvant antiandrogen therapy allowed
Radiotherapy:
No prior radiotherapy
No prior pelvic irradiation
Surgery:
No prior radical surgery for carcinoma of the prostate
Clareo Health | Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
